Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Felix Biotechnology Inc
Profile last edited on: 9/7/2022      CAGE: 8JL70      UEI: Y3JNYYQ5YHA6

Business Identifier: Programmable therapies to protect against coming threat of antimicrobial resistance
Year Founded
2020
First Award
2021
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

329 Oyster Point Boulevard 3rd Floor South
San Francisco, CA 94080
   (800) 234-5678
   info@felixbt.com
   www.felixbt.com
Location: Single
Congr. District: 14
County: San Francisco

Public Profile

With particular focus on accelerating the deployment of novel biotherapeutics targeting urgent microbial challenges in human health and beyond, In collaboration with researchers at Yale University and UC Berkeley, Felix Biotechnology is structured around management of infectious diseases

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$870,411
Phase II Dollars
$0
Total Awarded
$870,411

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $484,424
Project Title: Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization
2022 1 NIH $314,411
Project Title: Microfluidics Platform for Rapid, High-throughput Screening of Therapeutic Bacteriophages Based on Patient Bacterial Isolates
2021 1 NSF $256,000
Project Title: Leveraging machine learning to enable generalized phage therapy for pulmonary infections

Key People / Management

  Robert McBride -- Co-Founder & CEO

  Jonathan Kotula -- Head of Science

  Natalie Ma -- Former Head of Business Development, Interim Head of Clinical Development

  Lauren Richardson -- Head of Communications and Operations

  Paul Turner -- Co-Founder

Company News

There are no news available.